Johnson & Johnson said Friday that it completed its $894 million acquisition of Los Angeles cancer drug developer Cougar Biotechnology Inc.

Johnson & Johnson said that 20.1 million of Cougar’s shares were tendered in favor of the buyout by the Thursday deadline, which represents almost 96 percent of outstanding shares.

The New Brunswick, N.J. health care giant said in May it had agreed to buy Cougar, which is in late-stage trials on a potential vaccine for prostate cancer, for $43 per share.

Cougar now is a wholly owned subsidiary of Johnson & Johnson, and will work with the Ortho Biotech Oncology Research and Development unit. Chief Executive Alan Auerbach earlier announced he would stay through the transition.